Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Oliver Dorigo

Stanford University School of Medicine

United States

Research Interests

Explore related searches

Articles (18)

Collaborators (6)

James Ford

Stanford University

UNITED STATES

Crystal L. Mackall

Stanford University School of Medicine

UNITED STATES

Chien-Kuang Ding

Assistant Professor

University of California, San Francisco

UNITED STATES

Isabel Beshar

The University of Texas MD Anderson Cancer Center

UNITED STATES

Supreeti Tallapragada

Life Science Research Professional 3

Stanford University

UNITED STATES

William Rodgers

Weill Cornell Medicine

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Oliver Dorigo

Research Interests

Explore related searches

Articles (18)

Collaborators (6)

James Ford

Crystal L. Mackall

Chien-Kuang Ding

Isabel Beshar

Supreeti Tallapragada

William Rodgers

Make your next move.

Oliver Dorigo

Research Interests

Explore related searches

Articles (18)

B7H3 CAR T cell therapy across immunocompetent ovarian cancer models with evidence of transferable anti-tumor immunity

Initial results from a phase 1 study of PHST001, a macrophage activating anti-CD24 antibody, in patients with advanced/metastatic solid tumors

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer

Fertility-sparing treatment for atypical polypoid adenomyoma

Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma

Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report

Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity Free

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN'S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)

Germline genetic testing in patients with uterine serous carcinoma at a tertiary academic center.

Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab

Obesity, demographic, and lifestyle risk factor patterns associated with endometrial cancer diagnosis and survival: insights from the Women's Health Initiative

Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

Sensitizing mouse ovarian cancer tumors to immunotherapy

Monocytes: A Promising New TRAIL in Ovarian Cancer Cell Therapy

Collaborators (6)

James Ford

Crystal L. Mackall

Chien-Kuang Ding

Isabel Beshar

Supreeti Tallapragada

William Rodgers

Make your next move.